evipedia.ai
← Back

Rapamycin for Health & Longevity

Evidence Review created on 10/23/2026 using AI4L / Opus 5.5

Also known as: Sirolimus, Rapamune, Fyarro, Hyftor, AY-22989

Motivation

Rapamycin (sirolimus) is a prescription drug first isolated from soil bacteria on Easter Island and used for decades to prevent rejection of transplanted kidneys. It draws interest from people focused on longevity because it turns down a central growth switch inside cells that is closely tied to aging in laboratory animals. For risk-aware adults who already manage diet, exercise and sleep, it is one of the few existing medicines studied as a possible way to slow aging itself.

Interest grew after a coordinated mouse program run at several independent laboratories tested the drug started late in life. Since then, use outside its approved purposes has spread, usually as a once-weekly dose prescribed through longevity clinics and online services. Small human trials now examine its effects on immune function and body composition in healthy older adults, while questions about side effects remain open.

This review examines the human and animal evidence on rapamycin for health and longevity: expected benefits, risks and side effects, dosing regimens in use, interactions, and how use can be monitored, so that its potential can be set against its documented costs.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of rapamycin for longevity from expert podcasts, articles and opinion papers.

  • #272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more – David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D. - Peter Attia

    Two leading rapamycin researchers discuss the drug’s history, possible lifespan benefits, dosing, the Dog Aging Project and unanswered questions about human use, with Attia’s cautious clinical perspective.

  • Rapamycin - FoundMyFitness

    A referenced overview of rapamycin’s discovery, its action on the mTOR (mechanistic target of rapamycin, a cellular growth-control enzyme) pathway, animal and human longevity data, and adverse effects, including mixed immune findings.

  • The Rapamycin Story - Ross Pelton

    An interview with a pharmacist and rapamycin book author on animal lifespan data, the vaccine-response trial of everolimus (a rapamycin derivative) and mTOR; Life Extension sells supplements marketed as alternatives to the drug.

  • Results of a Crowdfunded One-Year Human Rapamycin Trial - Josh Conway

    Lifespan.io, which crowdfunded the PEARL trial run by rapamycin prescriber AgelessRx, summarizes its 48-week results: a null primary outcome, signals mainly in women, and the poor absorption of the compounded drug used.

  • Rapamycin for longevity: opinion article - Blagosklonny, 2019

    The leading proponent of rapamycin as a longevity drug argues that its side effects are reversible and avoidable; the primary source for the case for current use.

Chris Kresser mentions rapamycin only in passing (e.g., his podcast with Mark Hyman) and has no in-depth coverage. Andrew Huberman has no dedicated rapamycin episode; the rapamycin discussion found is a segment of his guest episode with Peter Attia, whose dedicated episode is listed above. Rhonda Patrick’s dedicated Q&A episode is members-only, so her open topic article is listed instead.

Grokipedia

  • Sirolimus

    An AI-generated encyclopedia entry covering approved uses, adverse effects, interactions, how the body handles the drug and a research subsection on longevity and aging; a broad orientation rather than a primary source.

Examine

No Examine article on rapamycin or sirolimus exists. Examine.com does not typically cover prescription medications, and rapamycin is a prescription-only drug.

ConsumerLab

No ConsumerLab article on rapamycin exists. ConsumerLab does not typically cover prescription medications, and rapamycin is a prescription-only drug.

Systematic Reviews

These systematic reviews and meta-analyses cover rapamycin’s effects on aging in humans and animals and its principal risk, excess mortality.

Mechanism of Action

Rapamycin binds the intracellular protein FKBP12 (FK506-binding protein 12, a drug-carrying partner protein), and the complex inhibits mTOR complex 1 (mTORC1, the nutrient-sensing hub that drives protein synthesis and cell growth) (Rapamune prescribing information). Lower mTORC1 activity increases autophagy (the cell’s recycling of damaged components), slows growth-factor-driven proliferation of immune and other cells, and dampens secretions of senescent cells (aged cells that have stopped dividing).

  • Competing explanations: Proponents argue that aging is driven partly by overactive growth signaling that rapamycin damps (Blagosklonny, 2019). The original mouse investigators noted that lifespan gains may reflect postponed cancer deaths, slowed aging, or both (Harrison et al., 2009).
  • Selectivity and mTORC2: Rapamycin acutely targets mTORC1, but chronic exposure also disrupts mTOR complex 2 (mTORC2, a second mTOR complex that helps relay insulin signals), which in mice impaired the liver’s response to insulin independently of lifespan (Lamming et al., 2012). Intermittent weekly dosing is hypothesized to spare mTORC2, which remains unproven in humans (Konopka & Lamming, 2023).
  • Pharmacokinetics: Oral bioavailability (the share of a dose reaching the blood) is about 14% for the solution, about 27% higher for tablets; the drug concentrates in red blood cells (blood-to-plasma ratio 36) and is 92% protein-bound. It is metabolized by CYP3A4 (a gut and liver enzyme that breaks down many drugs) and pumped back into the gut by P-glycoprotein (P-gp, a drug-efflux transporter); terminal half-life is about 62 hours (Rapamune prescribing information), and 69 hours with weekly dosing (Wallgren et al., 2026).

Historical Context & Evolution

Rapamycin was discovered in the 1970s from Streptomyces hygroscopicus bacteria in soil from Easter Island (Rapa Nui) and was first recognized as an antifungal and immunosuppressive agent (Roark & Iffland, 2025). Its suppression of immune-cell proliferation led to U.S. approval in 1999 for preventing kidney transplant rejection, supported by registration trials behind the manufacturer’s label, such as Kahan, 2000; it was later approved for lymphangioleiomyomatosis (a rare, progressive cystic lung disease) (Rapamune prescribing information).

Longevity interest grew from basic biology. Inhibiting the TOR (target of rapamycin) pathway extended lifespan in yeast, worms and flies, and in 2009 a National Institute on Aging testing program reported that rapamycin started at 600 days of age extended mouse lifespan at three independent sites (Harrison et al., 2009). Later work found dose- and sex-dependent effects (Miller et al., 2014) and lasting gains from a three-month course in middle-aged mice (Bitto et al., 2016).

Human translation began with Novartis-run immune trials of the derivative everolimus (Mannick et al., 2014) and small safety trials, and prescribing outside approved uses spread, per a survey with AgelessRx and Optispan co-authors (Kaeberlein et al., 2023). Because sirolimus is an approved generic, no manufacturer has a financial incentive to fund large longevity trials and payers have none to cover preventive use, so most human data come from small academic studies or companies that sell prescriptions. Opinion has shifted from viewing rapamycin purely as an immunosuppressant toward a dose-dependent immune modulator, but no outcome trial in healthy people has settled it.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: replicated controlled trials exist only for daily transplant regimens combined with other immunosuppressants, which are indirect for weekly longevity use.

Medium 🟩 🟩

Lean Mass and Self-Rated Health in Healthy Older Adults ⚠️ Conflicted

In the 48-week PEARL trial (Moel et al.), run by rapamycin prescriber AgelessRx, 114 healthy adults aged 50–85 took compounded rapamycin 5 or 10 mg weekly or placebo; primary-outcome visceral fat was unchanged. Women on 10 mg (n=8) gained lean mass and reported less pain on the SF-36 (a validated quality-of-life questionnaire); the abstract’s 5 mg emotional well-being gain also occurred on placebo in the full text. The 13-week RAPA-EX-01 trial (Stanfield et al.), with an Optispan co-author, found no SF-36 benefit. Net, this is an unreplicated subgroup signal.

Magnitude: Lean tissue mass in women on 10 mg rose 6.2 percentage points more than placebo at 48 weeks (95% CI, confidence interval or range likely to contain the true effect, 0.9–11.5), measured by DXA (dual-energy X-ray absorptiometry, a body-composition scan) (Moel et al., 2025); SF-36 physical component differed by −2.76 points versus placebo in RAPA-EX-01 (95% CI −8.81 to 3.32) (Stanfield et al., 2026).

Low 🟩

Prevention of Kidney Transplant Rejection ⭕️ Not Central to Health & Longevity

Sirolimus is approved to prevent kidney transplant rejection (Rapamune prescribing information). Two double-blind registration trials of the manufacturer, Wyeth (now Pfizer) (Kahan; MacDonald), found fewer biopsy-confirmed rejections. Evidence is indirect: daily 2–5 mg doses added to cyclosporine and corticosteroids. This bears on transplant medicine, not longevity.

Magnitude: Biopsy-confirmed acute rejection at 6 months was 16.9% (2 mg) and 12.0% (5 mg) versus 29.8% with azathioprine (Kahan, 2000), and 24.7% and 19.2% versus 41.5% with placebo (MacDonald, 2001).

Fewer Acute Graft-Versus-Host Reactions After Stem-Cell Transplantation ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Adding sirolimus to stem-cell transplant prevention regimens lowered graft-versus-host disease (donor cells attacking the host) in trials (Armand et al.; Kornblit et al.) and a meta-analysis (Chen et al.), not when replacing methotrexate (Cutler et al.). Evidence is indirect: daily multi-drug regimens. Net, a moderate reduction is likely in transplantation.

Magnitude: Grade II–IV acute graft-versus-host disease risk ratio (relative likelihood of the event) 0.75 (95% CI 0.68–0.82) versus regimens without sirolimus (Chen et al., 2021); 26% versus 34%, not significant, with sirolimus replacing methotrexate (Cutler et al., 2014).

Stabilized Lung Function in Lymphangioleiomyomatosis ⭕️ Not Central to Health & Longevity

Lymphangioleiomyomatosis (LAM, a rare cystic lung disease mainly of women) is driven by overactive mTOR signaling. In the MILES trial (McCormack et al.), lung function stabilized on sirolimus and declined after stopping. Evidence is indirect: daily dosing to transplant-range blood levels. This bears on a rare lung disease, not longevity.

Magnitude: FEV1 (forced expiratory volume in one second, a standard lung-function measure) changed by 153 mL more with sirolimus than with placebo over 12 months; the abstract reports no confidence interval (McCormack et al., 2011).

Lower Cancer Incidence ⚠️ Conflicted

Among kidney transplant recipients, sirolimus regimens had fewer cancers than other immunosuppressants, mainly non-melanoma skin cancers (Knoll et al.; Yanik et al.). Evidence is indirect: transplant doses, population and comparators. Yanik et al. found no effect on other cancers and more prostate cancer. Net, benefit for healthy users is unproven.

Magnitude: Malignancy HR 0.60 (95% CI 0.39–0.93) versus controls (Knoll et al., 2014); non-melanoma skin cancer IRR (incidence rate ratio, relative event rate) 0.49 (95% CI 0.32–0.76) but other cancers 1.06 (95% CI 0.69–1.63) (Yanik et al., 2015).

Improved Vaccine Response in Older Adults ⚠️ Conflicted

Low-dose everolimus, a rapamycin derivative, improved influenza vaccine responses in older adults in a Novartis trial (Mannick et al.). Evidence is indirect (derivative). A resTORbio phase 3 trial of the related inhibitor RTB101 (Mannick et al., 2021) found no fewer respiratory illnesses. Net, the immune signal is unconfirmed.

Magnitude: About 20% greater vaccine response with everolimus than placebo; no confidence interval reported (Mannick et al., 2014); respiratory illness in 26% versus 25% on placebo with RTB101 (OR, odds ratio, 1.07; 90% CI 0.80–1.42) (Mannick et al., 2021).

Fewer Repeat Coronary Procedures After Stenting ⭕️ Not Central to Health & Longevity

Coated stents release sirolimus locally, cutting repeat procedures without changing survival across 14 randomized trials (Kastrati et al.); that evidence is indirect (local delivery). A systematic review of 4 small oral-sirolimus studies after bare-metal stenting found less scar-tissue re-narrowing (Dasari et al.). This bears on coronary disease, not longevity.

Magnitude: Death, heart attack or repeat procedure HR 0.43 (95% CI 0.34–0.54), and death alone HR 1.03 (95% CI 0.80–1.30), versus bare-metal stents (Kastrati et al., 2007).

Improved Facial Angiofibromas in Tuberous Sclerosis ⭕️ Not Central to Health & Longevity

Sirolimus gel improves facial angiofibromas (benign skin growths) in tuberous sclerosis complex (a genetic disorder causing benign tumors), per a Cochrane review (Sasongko et al.) noting manufacturer support for most trials. Evidence is indirect: topical, not oral, use. This bears on a rare genetic skin condition, not on longevity.

Magnitude: Skin-lesion response risk ratio (relative likelihood of responding) 2.72 (95% CI 1.76–4.18) versus placebo across 2 trials (Sasongko et al., 2023).

Tumor Response in Malignant PEComa ⭕️ Not Central to Health & Longevity

In a single-arm trial with co-authors from its maker, Aadi Bioscience (Wagner et al.), intravenous albumin-bound sirolimus shrank tumors in malignant PEComa (perivascular epithelioid cell tumor, a rare aggressive connective-tissue cancer). Evidence is uncontrolled and indirect: intravenous, not oral, use. This bears on a rare cancer, not on longevity.

Magnitude: Overall response rate 39% (95% CI 22–58), no control group (Wagner et al., 2021).

Regression of Vascular Anomalies ⭕️ Not Central to Health & Longevity

Sirolimus, mostly taken by mouth, improved vascular anomalies (abnormal blood or lymph vessel growths) in a systematic review of 373 patients, mainly case reports and series (Freixo et al.). Evidence is largely uncontrolled and indirect: daily therapeutic dosing. This bears on rare vascular disorders, not on longevity.

Magnitude: Clinical improvement in 95.5% of patients with vascular tumors and Kasabach-Merritt phenomenon (a tumor-driven clotting disorder), size reduction in 88.9% with venous malformations and improvement in 94.9% with lymphatic malformations, no control group (Freixo et al., 2020).

Reduced Lupus Disease Activity ⭕️ Not Central to Health & Longevity

In systemic lupus erythematosus (an autoimmune disease attacking skin, joints and kidneys), sirolimus 1–3 mg daily lowered disease activity in a systematic review of 9 mostly observational studies with 145 patients (Ji et al.). Evidence is uncontrolled. This bears on an autoimmune disease, not on longevity.

Magnitude: Disease activity score (SLEDAI, a standard lupus activity index) fell by 4.85 points (95% CI 3.44–6.25) in 111 active patients, no control group (Ji et al., 2020).

Reduced Rheumatoid Arthritis Activity ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

A systematic review linked rapamycin-class drugs to improvement (Lin et al.). In an open-label trial of add-on sirolimus (Wen et al.), the full text, unlike the abstract, shows controls improving similarly. Evidence is indirect (add-on use) and bears on arthritis, not longevity. Net, benefit is unconfirmed.

Magnitude: Disease activity score (DAS28, a standard rheumatoid arthritis index) fell from 4.55 to 3.13 by week 24 with sirolimus; the control group also improved, but its figures appear only graphically; not compared between groups (Wen et al., 2019).

Shrinkage of Renal Angiomyolipoma ⭕️ Not Central to Health & Longevity

Sirolimus shrank renal angiomyolipomas (benign fatty kidney tumors) in tuberous sclerosis complex or LAM in a systematic review of 4 prospective uncontrolled studies with 94 patients (Peng et al.). Tumors tended to regrow after stopping. Evidence is indirect: daily therapeutic dosing. This bears on rare tumor conditions, not longevity.

Magnitude: Tumor response in 46.8% (44 of 94) in the first year, no control group (Peng et al., 2014).

Survival After Liver Transplantation for Liver Cancer ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

In liver recipients with hepatocellular carcinoma (primary liver cancer), sirolimus- or everolimus-based regimens improved survival in a 17-study meta-analysis (Yan et al.). Evidence is indirect (pooled everolimus). The label reports excess deaths and graft loss with sirolimus started at transplantation. This bears on transplantation, not longevity; net benefit is uncertain.

Magnitude: 5-year overall survival risk ratio (relative likelihood of surviving) 1.13 (95% CI 1.02–1.26) in randomized trials (Yan et al., 2022); with tacrolimus started at liver transplantation, excess mortality and graft loss occurred in 22% versus 9% on tacrolimus alone (Rapamune prescribing information).

Fewer Cytomegalovirus Infections After Kidney Transplantation ⭕️ Not Central to Health & Longevity

In kidney recipients, sirolimus- or everolimus-based regimens had fewer cytomegalovirus (a herpes-family virus dangerous after transplantation) infections than calcineurin-inhibitor (standard anti-rejection drugs such as tacrolimus) regimens across 28 randomized trials (Mallat et al.). Evidence is indirect: pooled everolimus, transplant doses. This bears on transplant infection control, not longevity.

Magnitude: Cytomegalovirus infection risk ratio (relative likelihood of infection) 0.54 (95% CI 0.41–0.72) versus calcineurin-inhibitor regimens (Mallat et al., 2017).

Better Kidney Function Than Calcineurin-Inhibitor Regimens ⭕️ Not Central to Health & Longevity

In kidney recipients, sirolimus- or everolimus-based regimens replacing calcineurin inhibitors preserved kidney function better across randomized trials, at the cost of more acute rejections, proteinuria (urinary protein loss) and wound complications (Mallat et al.). Evidence is indirect: pooled everolimus, transplant doses. This bears on transplant kidney function, not longevity.

Magnitude: eGFR (estimated glomerular filtration rate, a standard kidney-function measure) 4.07 mL/min per 1.73 m² higher (95% CI 1.34–6.80) than with calcineurin-inhibitor regimens (Mallat et al., 2017).

Speculative 🟨

Reduced Skin Aging Markers with Topical Use

In a placebo-controlled trial at Drexel University (Chung et al.), topical rapamycin lowered p16 (a marker of senescent cells) and raised collagen VII in aged skin; 19 of 36 dropped out. Basis: unvalidated biomarkers only.

Extended Lifespan in Animals

Rapamycin extended lifespan in genetically diverse mice at three sites even when started late (Harrison et al.); a vertebrate meta-analysis agrees (Ivimey-Cook et al.). No human lifespan data exist; the basis is animal data.

Improved Cardiac Function

Ten weeks of low-dose rapamycin improved heart ultrasound measures versus placebo in middle-aged dogs (Urfer et al.); an uncontrolled pilot in 6 older men reported better cardiac scan measures (Moody et al.). Basis: unvalidated measures.

Periodontal Rejuvenation

Short-term rapamycin regenerated periodontal (tooth-supporting) bone, reduced gum inflammation and shifted the oral microbiome toward a younger profile in aged mice (An et al.). Human data are absent; the basis is animal data.

Increased Cerebral Blood Flow in APOE4 Carriers

Over 4 weeks, 1 mg daily raised brain blood flow over 15% in 9 APOE4 carriers (a cholesterol-transport gene variant raising Alzheimer’s risk), not non-carriers (Aware et al.). Uncontrolled pilot; unvalidated biomarker.

Benefit-Modifying Factors

  • Genetics: Mouse lifespan gains were larger in hybrid than inbred strains (Swindell, 2017). In humans, APOE4 carriers showed brain blood-flow increases that non-carriers lacked (Aware et al., 2026); variants of CYP3A5 (a drug-metabolizing enzyme) alter drug exposure (see Risk-Modifying Factors).
  • Baseline biomarkers: PEARL investigators attributed the null visceral-fat result partly to lean, health-conscious participants, suggesting effects may depend on higher baseline adiposity, which is untested (Moel et al., 2025).
  • Sex: Female mice gained more survival than males (HR 0.41 versus 0.63) (Swindell, 2017); in PEARL, lean-mass and pain benefits appeared only in women, a small subgroup (Moel et al., 2025).
  • Pre-existing conditions: Established benefits are confined to kidney transplantation, LAM and rare tumor conditions. In early Alzheimer’s disease, 8 weeks of 1 mg daily produced no cognitive change (Gonzales et al., 2025).
  • Age: Mouse benefit persisted when started at 600 days (Harrison et al., 2009), with peak benefit in early senescence (Swindell, 2017). In adults aged 70–95, 1 mg daily for 8 weeks left physical, cognitive and most immune measures unchanged (Kraig et al., 2018).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: replicated controlled adverse-event data exist only at daily transplant and LAM doses, which are indirect for weekly longevity regimens, while weekly regimens have been tested only in single small trials.

Medium 🟥 🟥

Mouth Ulcers (Stomatitis)

Painful mouth sores (stomatitis, inflammation of the oral lining) are a class effect of mTOR inhibition and were among the most common adverse reactions in the LAM trial (prescribing information). In a survey of 333 users and 172 non-users (Kaeberlein et al.; co-authors from AgelessRx and Optispan, companies in the rapamycin field), mouth ulceration was the only condition significantly more common in users; most ulcers were transient (Hudson et al.). LAM doses exceed weekly longevity doses, a gap that limits transfer.

Magnitude: In the LAM trial, stomatitis affected at least 20% of sirolimus recipients, more than placebo; the placebo rate is not stated (Rapamune prescribing information). In the user survey, about 26% of rapamycin users reported oral health changes; this figure has no non-user comparison (Hudson et al., 2024).

Raised Blood Lipids ⚠️ Conflicted

Sirolimus raises cholesterol and triglycerides. In the transplant registration trials (Kahan; MacDonald), lipid-lowering treatment was needed far more often than with placebo or azathioprine, at daily doses above longevity regimens. At 6 mg weekly, RAPA-EX-01 (Stanfield et al.) found higher LDL (low-density lipoprotein, the main artery-clogging cholesterol) than placebo, and a systematic review found lipid rises in older people with disease (Lee et al.); PEARL reported lipids staying within normal ranges (Moel et al.). Net, a modest LDL rise is likely at longevity doses.

Magnitude: LDL 0.32 mmol/L higher than placebo at 13 weeks; no confidence interval reported (Stanfield et al., 2026). At transplant doses, lipid-lowering therapy was required in 42–52% versus 16% on placebo (Rapamune prescribing information).

Raised Blood Glucose ⚠️ Conflicted

Chronic rapamycin disrupts mTORC2, impairing insulin’s control of liver glucose output in mice (Lamming et al.). In registry data, kidney recipients on sirolimus developed diabetes more often (Johnston et al.). At weekly doses, RAPA-EX-01 found higher HbA1c (glycated hemoglobin, a three-month blood-sugar average) than placebo (Stanfield et al.), and PEARL a small HbA1c rise in men on 5 mg (Moel et al.); an 8-week trial of 1 mg daily found no change in glucose tolerance (Kraig et al.). Net, a small rise in blood sugar is likely.

Magnitude: HbA1c 1.74 mmol/mol higher than placebo at 13 weeks; no confidence interval reported (Stanfield et al., 2026). New-onset diabetes adjusted HR 1.36 (95% CI 1.09–1.69) to 1.66 (95% CI 1.42–1.93) versus non-sirolimus regimens in transplant registry data (Johnston et al., 2008); no change in oral glucose tolerance (Kraig et al., 2018).

Gastrointestinal, Joint and Muscle Pain, and Other Minor Adverse Events ⚠️ Conflicted

Nausea, diarrhea and abdominal discomfort are common with sirolimus. In PEARL, gastrointestinal symptoms were reported more often on rapamycin than placebo (Moel et al.), and in RAPA-EX-01 total and drug-related events were more frequent on sirolimus (Stanfield et al.). At transplant and LAM doses, the label also lists joint pain (arthralgia) and muscle pain (myalgia) above placebo. PEARL’s total adverse-event counts were, however, similar across groups (Moel et al.). Net, a higher burden of mild events is likely.

Magnitude: RAPA-EX-01: 99 versus 63 adverse events (incidence rate ratio 1.57, 95% CI 0.86–2.87) and possibly or probably drug-related events in 35% versus 15% (Stanfield et al., 2026); PEARL: gastrointestinal symptoms in 8 (10 mg) and 7 (5 mg) versus 4 placebo participants, total events 117 and 116 versus 122 (Moel et al., 2025); arthralgia in 25–31% versus 18% on placebo in transplant Study 2 (Rapamune prescribing information).

Blood Cell Count Changes ⚠️ Conflicted

Sirolimus suppresses blood-cell production. In adults aged 70–95 on 1 mg daily, hemoglobin, hematocrit (red-cell share of blood) and red-cell indices fell without clinical effects (Kraig et al.); RAPA-EX-01 found smaller red cells (Stanfield et al.). At transplant doses, anemia, thrombocytopenia (low platelet count) and leukopenia (low white-cell count) exceeded comparators (label; Webster et al.). PEARL instead found red-cell counts rising on 5 mg (Moel et al.). Net, mild blood-count changes are likely.

Magnitude: Mean red-cell volume 2.90 fL lower than placebo; no confidence interval reported (Stanfield et al., 2026). At transplant doses, anemia 23–33% and thrombocytopenia 14–30% versus 21% and 9% on placebo (Rapamune prescribing information); leukopenia risk ratio 2.02 (95% CI 1.12–3.66) when sirolimus-class drugs replaced calcineurin inhibitors (Webster et al., 2006).

Skin Rash and Acne

Rash and acne are labeled adverse reactions of sirolimus; acne was among the most common reactions exceeding placebo in the LAM trial, per the prescribing information. In adults aged 70–95 on 1 mg daily, one rapamycin participant developed a facial rash (Kraig et al.). Transplant and LAM doses exceed weekly longevity doses, a gap that limits transfer.

Magnitude: Rash in 10–20% versus 6% on placebo in transplant Study 2 (Rapamune prescribing information).

Low 🟥

Fluid Accumulation and Impaired Wound Healing

Sirolimus inhibits fibroblast (connective-tissue cell) proliferation, delaying wound healing, and causes lymphocele (lymph-fluid collection), peripheral edema (limb swelling) and effusions (fluid around lungs or heart) (prescribing information). A randomized kidney transplant trial found more wound complications than tacrolimus (Dean et al.). Evidence is indirect: daily doses within multi-drug transplant regimens.

Magnitude: Peripheral edema in 54–58% versus 48% on placebo in transplant Study 2 (Rapamune prescribing information); wound complications in 47% versus 8% with tacrolimus (Dean et al., 2004).

Infections ⚠️ Conflicted

At transplant doses, sirolimus carries a boxed infection warning (prescribing information); that evidence is indirect (combined immunosuppression). At 6 mg weekly, one RAPA-EX-01 participant was hospitalized with pneumonia (Stanfield et al.), while PEARL found similar cold and flu-like illness (Moel et al.). Net, excess infection at longevity doses is unproven.

Magnitude: Serious pneumonia in 1 of 20 on sirolimus versus 0 of 20 on placebo (Stanfield et al., 2026); urinary tract infection in 26–33% versus 26% on placebo at transplant doses (Rapamune prescribing information).

Increased Mortality in Kidney Transplant Recipients ⚠️ Conflicted

A patient-level meta-analysis of 21 kidney transplant trials (Knoll et al.) found higher mortality with sirolimus; a Cochrane review of 33 trials (Webster et al.) found no significant difference. Evidence is indirect: daily doses combined with other immunosuppressants. Net, excess deaths are likely in transplant recipients, unmeasured at longevity doses.

Magnitude: HR 1.43 for death versus controls (95% CI 1.21–1.71) (Knoll et al., 2014); no significant difference, with no pooled figure in the abstract, in the Cochrane review (Webster et al., 2006).

Reduced Testosterone and Fertility

Male heart transplant recipients on sirolimus had lower testosterone and higher gonadotropins (pituitary hormones that drive the testes) than matched controls (Kaczmarek et al.). The label warns of azoospermia (absence of sperm), menstrual disorders and ovarian cysts. Evidence is indirect: daily doses within multi-drug transplant regimens.

Magnitude: Mean testosterone 3.86 versus 4.55 ng/mL in matched controls (Kaczmarek et al., 2004).

Proteinuria

Sirolimus can increase urinary protein loss, occasionally to nephrotic range (heavy loss causing swelling), per a kidney transplant conversion trial in the label. PEARL found higher BUN (blood urea nitrogen, a kidney-function marker) in men on 10 mg (Moel et al.). Evidence is indirect: transplant doses with other immunosuppressants.

Magnitude: Nephrotic-range proteinuria in 9.2% versus 3.7% continuing calcineurin inhibitors (Rapamune prescribing information).

Venous Thromboembolism

Sirolimus may raise the risk of blood clots in deep veins or lungs (venous thromboembolism). A randomized lung transplant trial (Ahya et al.) and a matched heart transplant cohort (Thibodeau et al.) found more clots. Evidence is indirect: daily doses within multi-drug transplant regimens.

Magnitude: Venous thromboembolism in 17.2% (15 of 87) on sirolimus versus 3.2% (3 of 94) on azathioprine, adjusted HR 5.2 (95% CI 1.4–19.5), in lung transplant recipients (Ahya et al., 2011).

Veno-Occlusive Disease and Thrombotic Microangiopathy After Stem-Cell Transplantation ⚠️ Conflicted

After donor stem-cell transplantation, meta-analyses (Wang et al.; Chen et al.) found more veno-occlusive disease (blockage of small liver veins) with sirolimus; thrombotic microangiopathy (small-vessel clotting) rose significantly in one only. Evidence is indirect: daily doses with calcineurin inhibitors and chemotherapy. Net, vessel injury is likely in this setting.

Magnitude: Sinusoidal obstruction syndrome (another name for veno-occlusive disease) risk ratio 2.24 (95% CI 1.26–4.01) and thrombotic microangiopathy risk ratio 2.48 (95% CI 0.87–7.06) versus regimens without sirolimus (Wang et al., 2015); both increased (p < 0.00001; p-value, the probability of such a result by chance alone) in Chen et al., 2021, which reports no pooled figure in its abstract.

Lymphoma and Other Cancers ⚠️ Conflicted

The label’s boxed warning cites possible lymphoma from immunosuppression at transplant doses, and in female mice one rapamycin dose shifted cancers toward aggressive blood cancers (Bitto et al.). Randomized transplant data show fewer cancers overall (Knoll et al.). Net, excess cancer risk is unsupported at doses studied.

Magnitude: Lymphoma in 0.7–3.2% on sirolimus versus 0.6–0.8% in comparator arms (Rapamune prescribing information); malignancy HR 0.60 (95% CI 0.39–0.93) (Knoll et al., 2014).

Interstitial Pneumonitis

Non-infectious lung inflammation (interstitial pneumonitis), some cases fatal, has occurred with sirolimus, possibly more often at higher trough levels (lowest blood levels before the next dose) (prescribing information). In a heart transplant case series, 3 of 30 developed it, resolving after stopping (Delgado et al.). Data are transplant doses, uncontrolled.

Magnitude: Pneumonitis in 3 of 30 (10%) heart transplant recipients on sirolimus, no control group (Delgado et al., 2006); the Rapamune prescribing information reports cases without a defined denominator.

Liver Injury

Liver injury, including fatal hepatic necrosis (death of liver tissue) at elevated trough levels, appears among post-marketing reports in the prescribing information. In a kidney recipient, raised liver enzymes normalized after switching drugs (Niemczyk et al.). Data are transplant-dose case reports.

Magnitude: Not quantified in available studies. Only post-marketing and single case reports exist, without a denominator or comparison group (Niemczyk et al., 2005).

Hypersensitivity and Angioedema

Sirolimus can cause hypersensitivity reactions, including anaphylaxis (severe allergic reaction) and angioedema (rapid swelling of face, lips or airway), possibly more so with ACE (angiotensin-converting enzyme) inhibitor blood-pressure drugs (prescribing information). Among 80 kidney recipients on sirolimus, 12 had angioedema, once life-threatening (Mahé et al.). Data are transplant doses, uncontrolled.

Magnitude: Angioedema in 15% (12 of 80) of kidney recipients on sirolimus; no control group (Mahé et al., 2007).

Posterior Reversible Encephalopathy Syndrome

Posterior reversible encephalopathy syndrome (brain swelling causing seizures and vision loss) appears among post-marketing reports in the prescribing information. In a kidney recipient, it resolved within 2 months after stopping rapamycin (Qin et al.). Data are transplant-dose case reports.

Magnitude: Not quantified in available studies. Only post-marketing and single case reports exist, without a denominator or comparison group (Qin et al., 2011).

Blunted Exercise Gains

In RAPA-EX-01, 40 sedentary adults aged 65–85 on 6 mg weekly plus home exercise improved chair-stand performance less than placebo; the primary analysis was not significant, the per-protocol analysis (adherent participants only) was (Stanfield et al.). mTORC1 drives post-exercise muscle protein synthesis (Lin et al.).

Magnitude: −2.13 chair-stand repetitions versus placebo (95% CI −4.61 to 0.34; intention-to-treat, analysing all as randomized) and −3.44 (95% CI −5.86 to −0.99; per-protocol) (Stanfield et al., 2026); muscle protein synthesis reduction from Lin et al., 2022.

Raised Blood Pressure ⚠️ Conflicted

The label lists hypertension as a common reaction, yet in transplant Study 2 it was no more frequent than on placebo. In an uncontrolled early-Alzheimer’s pilot, 1 mg daily for 8 weeks raised systolic blood pressure (Gonzales et al.). Net, a rise at longevity doses is unproven.

Magnitude: Hypertension in 45% (2 mg) and 49% (5 mg) versus 48% on placebo in transplant Study 2 (Rapamune prescribing information); the pilot gives no figure in its abstract and has no control group (Gonzales et al., 2025).

Speculative 🟨

Embryo-Fetal Harm

Animal data show fetal toxicity, and the label requires highly effective contraception during use and for 12 weeks after the last dose. No controlled human pregnancy data exist; the basis is animal studies.

Rise in Brain-Injury Biomarkers

In 10 adults with early Alzheimer’s, 8 weeks of 1 mg daily raised spinal-fluid markers of tau (an Alzheimer’s tangle protein) and nerve injury without cognitive change (Gonzales et al.). Basis: one uncontrolled pilot.

Gut Dysbiosis

PEARL found a small rise in a commercial gut dysbiosis (microbial imbalance) score in men on 10 mg and a trend toward higher intestinal permeability in women (Moel et al.). Unvalidated consumer biomarkers only.

Risk-Modifying Factors

  • Genetics: Carriers of at least one CYP3A51 allele (an active form of a drug-metabolizing enzyme) cleared sirolimus faster and needed higher doses for the same blood level; *3/3 carriers reach higher exposure per milligram (Le Meur et al., 2006).
  • Baseline biomarkers: Pre-existing high cholesterol, triglycerides or HbA1c raise the chance that drug-induced rises cross treatment thresholds; PEARL excluded untreated dyslipidemia (abnormal blood fats), anemia, neutropenia (low neutrophil count) and thrombocytopenia (Moel et al., 2025).
  • Sex: Women of reproductive potential face embryo-fetal risk, menstrual disorders and ovarian cysts; men may develop azoospermia (Rapamune prescribing information) or lower testosterone (Kaczmarek et al., 2004). PEARL found no sex difference in adverse-event counts (Moel et al., 2025).
  • Pre-existing conditions: Hepatic impairment raised exposure 43%, 94% and 189% in Child-Pugh A, B and C (mild, moderate, severe liver dysfunction) (Rapamune prescribing information); diabetes, chronic infection, immune deficiency, planned surgery and proteinuric kidney disease amplify the matching risks.
  • Age: Adults aged 70–95 showed red-cell declines on 1 mg daily (Kraig et al., 2018); the label advises starting at the low end of dosing in older adults because organ dysfunction is more frequent.

Key Interactions & Contraindications

Prescription drugs

  • Strong CYP3A4/P-gp inhibitors (ketoconazole, voriconazole, itraconazole, clarithromycin, erythromycin, telithromycin): Avoid. Ketoconazole raised sirolimus exposure 10.9-fold, risking toxicity; the label advises alternatives with less interaction potential (Rapamune prescribing information).
  • Other label-listed CYP3A4/P-gp inhibitors (diltiazem, verapamil, fluconazole, nicardipine, danazol, ritonavir): Monitor. Diltiazem raised exposure 1.6-fold, increasing side-effect risk; mitigation is blood-level checks and dose reduction (Rapamune prescribing information).
  • Strong CYP3A4/P-gp inducers (rifampin, rifabutin): Avoid. Rifampin cut exposure by 82%, risking loss of effect; the label advises agents with less enzyme induction (Rapamune prescribing information).
  • Other label-listed CYP3A4/P-gp inducers (carbamazepine, phenytoin, phenobarbital, rifapentine): Caution. They can lower sirolimus levels, risking loss of effect; mitigation is blood-level checks and dose adjustment (Rapamune prescribing information).
  • Calcineurin inhibitors (cyclosporine, tacrolimus): Caution. Cyclosporine raises sirolimus levels (take sirolimus 4 hours after it), and the combination increases hemolytic uremic syndrome and thrombotic thrombocytopenic purpura (clotting disorders damaging kidneys and blood cells) (Rapamune prescribing information).
  • ACE inhibitors (angiotensin-converting enzyme inhibitors, blood-pressure drugs such as lisinopril, ramipril, enalapril): Caution. Co-use increases angioedema (rapid swelling of face, lips or airway); mitigation is stopping at the first sign of swelling (Rapamune prescribing information).
  • Statins and fibrates (lipid-lowering drugs such as atorvastatin, simvastatin, fenofibrate): Monitor. Statin co-administration produced creatine kinase (a muscle-damage marker) elevations in 3%, myalgia (muscle pain) in 6.7% and rhabdomyolysis (muscle breakdown) in under 1%; mitigation is monitoring for muscle symptoms (Rapamune prescribing information).
  • Live vaccines (measles-mumps-rubella, yellow fever, varicella, oral typhoid, BCG tuberculosis vaccine): Avoid during treatment; vaccine response may also be reduced. Mitigation is completing live vaccines before starting (Rapamune prescribing information).

Over-the-counter medications

  • Cimetidine (acid reducer) and clotrimazole (antifungal): Monitor. Both are listed as raising sirolimus concentrations, increasing side-effect risk; mitigation is blood-level checks when starting or stopping them (Rapamune prescribing information).
  • Cannabidiol (CBD, a cannabis-derived compound): Monitor. Co-use can raise sirolimus levels and toxicity; the label advises drug-level monitoring and dose reduction (Rapamune prescribing information).

Supplements and foods

  • St. John’s wort: Caution. It induces CYP3A4 and P-gp and can lower sirolimus levels, risking loss of effect; mitigation is avoiding it or checking blood levels (Rapamune prescribing information).
  • Grapefruit juice: Avoid per label. It raised sirolimus exposure about 350% in a pharmacokinetic study, producing unpredictable, higher levels that risk toxicity (Cohen et al., 2012; Rapamune prescribing information).
  • Resveratrol: Monitor. Added at up to 1,000 mg daily to sirolimus in an open-label LAM trial, it was tolerated with some gastrointestinal side effects (Gupta et al., 2023).
  • Supplements with additive mTOR-suppressing or CYP3A4-inhibiting effects (berberine, goldenseal): Caution (theoretical). They may add to mTOR inhibition or raise sirolimus levels, increasing side-effect risk; mitigation is blood-level checks if combined.
  • High-fat meals: Monitor. A high-fat meal raised exposure 23–35%, so inconsistent meals shift side-effect risk; mitigation is consistent dosing with or without food (Rapamune prescribing information).

Other interventions

  • Surgery and dental procedures: Caution. Impaired wound healing and lymphocele were reported after transplant surgery (Rapamune prescribing information); PEARL excluded people with major surgery planned within 12 months (Moel et al., 2025). Pausing around procedures is common practice.
  • Resistance and endurance training: Monitor. Weekly sirolimus trended toward smaller functional gains from home exercise in older adults (Stanfield et al., 2026).

Populations who should avoid Rapamycin:

  • Hypersensitivity to sirolimus, its only labeled contraindication (Rapamune prescribing information)
  • Pregnancy, breastfeeding, or women of reproductive potential without highly effective contraception during use and for 12 weeks after the last dose (Rapamune prescribing information)
  • Liver or lung transplant recipients (boxed warning: excess mortality, hepatic artery thrombosis or clotting of the liver’s artery, and breakdown of airway surgical joins) (Rapamune prescribing information)
  • Children under 13 years, below the labeled age range (Rapamune prescribing information)
  • Anemia (hemoglobin below 9.0 g/dL), leukopenia (white cells below 3,500/mm³), neutropenia (neutrophils below 2,000/mm³) or thrombocytopenia (platelets below 125,000/mm³); chronic infections requiring ongoing treatment (e.g., human immunodeficiency virus); immune deficiency; major surgery within 12 months or chronic open wounds; untreated dyslipidemia (e.g., total cholesterol above 350 mg/dL or triglycerides above 880 mg/dL); poorly controlled (HbA1c above 7%) or insulin-dependent diabetes; glomerular filtration rate below 30; impaired liver function (PEARL exclusions) (Moel et al., 2025; PEARL registry record NCT04488601)
  • Severe hepatic impairment (Child-Pugh C, exposure +189%) unless the dose is reduced and levels monitored (Rapamune prescribing information)

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Baseline and early laboratory checks: Lipids, glucose, blood count, creatinine and ALT (a liver enzyme) before starting and at 2 and 4 weeks, with HbA1c at baseline, as in PEARL (Moel et al., 2025), detect metabolic and blood-count changes early.
  • Lipid action thresholds: The label defines hypercholesterolemia as fasting cholesterol above 240 mg/dL and hypertriglyceridemia above 500 mg/dL and advises diet, exercise or lipid-lowering drugs if detected (Rapamune prescribing information), mitigating lipid-driven cardiovascular risk.
  • Commercial product and blood-level check: Using commercial tablets and measuring sirolimus 48 hours after a dose (Wallgren et al., 2026) prevents under- or overdosing from compounded products delivering about 31% of expected levels, per AgelessRx researchers (Harinath et al., 2025).
  • Interaction screening: Reviewing every new prescription, antifungal, antibiotic and supplement against CYP3A4/P-gp lists prevents toxic or subtherapeutic levels (Rapamune prescribing information).
  • Pause for surgery and acute infection: Holding doses 1–2 weeks before and after surgery and during febrile infections reduces impaired wound healing and infection complications.
  • Dexamethasone mouthwash for mouth ulcers: Dexamethasone 0.5 mg/5 mL, 10 mL swished four times daily, cut grade 2 or worse everolimus-related stomatitis to 2% versus 33% in historical controls (Rugo et al., 2017); evidence is from the analogue everolimus.
  • Dental review: Regular dental checks, proposed by the authors for off-label users, help manage mouth ulcers and track oral health (Hudson et al., 2024).
  • Sun protection: Limiting ultraviolet exposure with clothing and broad-spectrum sunscreen mitigates the skin-cancer risk flagged in the label (Rapamune prescribing information).
  • Contraception and vaccination timing: Highly effective contraception during use and for 12 weeks afterwards prevents embryo-fetal harm; completing live vaccines before starting avoids vaccine-strain infection (Rapamune prescribing information).

Therapeutic Protocol

Each dose below is cited to its source; other parameters without a citation (timing, titration or stepwise dose adjustment, cycling) reflect common practice.

  • Weekly commercial sirolimus: Among weekly users surveyed, 6 mg once weekly was the most common dose, range 1–20 mg (Kaeberlein et al., 2023); RAPA-EX-01 tested 6 mg weekly in older adults (Stanfield et al., 2026).
  • Weekly compounded rapamycin: PEARL used 5 or 10 mg compounded weekly (Moel et al., 2025), roughly one-third as much commercial drug, because compounded capsules delivered about 31% of the blood level per milligram (Harinath et al., 2025).
  • Daily low dose (research regimen): 1 mg daily was used in trials of healthy older adults (Kraig et al., 2018), early Alzheimer’s disease (Gonzales et al., 2025) and APOE4 carriers (Aware et al., 2026).
  • Everolimus alternative: The derivative everolimus improved vaccine responses in older adults at relatively well-tolerated low doses (Mannick et al., 2014); it is a different drug with its own labeling.
  • Who popularized it: Mikhail Blagosklonny made the case for routine use (Blagosklonny, 2019); prescribing physician Alan Green and AgelessRx staff co-authored the user survey (Kaeberlein et al., 2023).
  • Grapefruit-boosted dosing (competing approach): Grapefruit juice raised exposure about 350% (Cohen et al., 2012); some users exploit this, but the label prohibits the combination and exposure becomes unpredictable.
  • Time of day: No study compares timing; a morning dose on a fixed weekday is common, taken consistently with or without food because a high-fat meal raises exposure 23–35% (Rapamune prescribing information).
  • Half-life: About 62 hours in transplant patients (Rapamune prescribing information) and 69 hours with weekly dosing, with pre-dose levels below the immunosuppressive range (Wallgren et al., 2026).
  • Single versus split dose: Longevity regimens use one weekly dose, giving a peak and a long low trough intended to spare mTORC2 (Konopka & Lamming, 2023); split weekly dosing has not been studied.
  • Genetic factors: CYP3A5*1 carriers need higher doses for equal exposure (Le Meur et al., 2006); a 48-hour blood level individualizes dosing regardless of genotype. APOE4 carriers are a target group in ongoing trials.
  • Sex: Female mice had larger lifespan gains (Swindell, 2017) and women showed PEARL’s only body-composition benefit (Moel et al., 2025); no sex-specific human dose exists.
  • Age: Trials enrolled adults up to 85–95 years (Kraig et al., 2018; Stanfield et al., 2026); the label advises starting at the low end of the range in older adults.
  • Baseline biomarkers: Elevated lipids or HbA1c, or low blood counts, leave less margin before drug-induced changes cross treatment thresholds; PEARL excluded untreated dyslipidemia and low blood counts (Moel et al., 2025).
  • Pre-existing conditions: Hepatic impairment requires dose reduction; LAM treatment starts at 2 mg daily titrated to trough levels of 5–15 ng/mL (Rapamune prescribing information).

Discontinuation & Cycling

  • Lifelong or short-term: Longevity use is intended as long-term, yet the longest controlled trial at longevity doses ran 48 weeks (Moel et al., 2025); in mice, a three-month mid-life course had lasting effects (Bitto et al., 2016).
  • Withdrawal effects: No withdrawal syndrome is described. In LAM, lung-function decline resumed after stopping (McCormack et al., 2011), so effects in that disease last only while the drug is taken.
  • Tapering: Not required; the 62-hour half-life produces a natural taper over about two weeks, and stopping abruptly is common practice.
  • Planned pauses: Common practice pauses dosing around surgery and during acute infections; for conception, the label requires stopping at least 12 weeks beforehand (Rapamune prescribing information).
  • Cycling for efficacy: Weekly dosing is itself intermittent; users also report intervals of 5–17 days (Kaeberlein et al., 2023). No trial shows that cycling maintains efficacy better than continuous use.

Sourcing and Quality

  • Prescription status: Sirolimus is prescription-only; brand Rapamune (Pfizer; 0.5, 1 and 2 mg tablets) and generic sirolimus approved through an abbreviated new drug application are regulated drug products, so third-party supplement testing does not apply (Rapamune prescribing information; generic sirolimus label).
  • Commercial versus compounded: Compounded capsules delivered about 31% of the blood level per milligram of commercial tablets (Harinath et al., 2025); compounded products vary by pharmacy, so milligram doses are not interchangeable.
  • Formulation handling: Tablets should not be crushed, chewed or split, which limits fine dose adjustment; the oral solution allows smaller increments (Rapamune prescribing information).
  • Reputable sources: Licensed pharmacies dispensing Rapamune or generic sirolimus; the compounding pharmacy Belmar Pharma Solutions supplied PEARL (Moel et al., 2025). Unregulated online imports risk counterfeit or mislabeled product.
  • Verification by blood test: A sirolimus blood level after dosing confirms the product delivers the expected exposure, useful when switching sources (Harinath et al., 2025).

Practical Considerations

  • Time to effect: No outcome benefit has a defined onset; PEARL body-composition signals appeared at 24 and 48 weeks (Moel et al., 2025), and everolimus vaccine effects after 6 weeks of dosing (Mannick et al., 2014). Lifespan effects cannot be observed in an individual.
  • Common pitfalls: Treating compounded and commercial milligrams as equivalent; combining with CYP3A4 inhibitors or grapefruit; skipping lipid and glucose checks; dosing through surgery or infection; and reading mouse lifespan data as proof of human benefit.
  • Regulatory status: Approved by the U.S. Food and Drug Administration for preventing kidney transplant rejection (age 13 and older) and LAM (Rapamune prescribing information); longevity use is off-label (outside approved indications) and needs a willing prescriber.
  • Access: Use requires a physician willing to prescribe outside approved indications, often through longevity clinics or telehealth services such as AgelessRx; 78–82% of surveyed users reported physician supervision (Kaeberlein et al., 2023).
  • Conflicts of interest: Much healthy-adult evidence comes from AgelessRx (PEARL, bioavailability study) and Optispan-affiliated researchers, organizations with commercial stakes in rapamycin’s adoption (Moel et al., 2025; Kaeberlein et al., 2023).

Interaction with Foundational Habits

  • Sleep: Direction: none established. No trial measured sleep; in the user survey 23.7% reported better sleep and 15.6% disagreed, self-reported and uncontrolled (Kaeberlein et al., 2023). Practical: morning dosing on a fixed weekday is common practice.
  • Nutrition: Direction: indirect. Rapamycin shares some effects with dietary restriction but is metabolically distinct (Miller et al., 2014). Because it raises LDL and glucose, limiting refined carbohydrate and saturated fat offsets those risks (common practice); grapefruit avoidance and consistent meal fat on dosing days follow the label.
  • Exercise: Direction: potentially blunting. Weekly 6 mg trended toward smaller gains from home exercise (Stanfield et al., 2026), consistent with mTORC1’s role in post-exercise muscle protein synthesis (Lin et al., 2022). Separating dosing from heavy resistance sessions by 1–2 days is common practice, untested.
  • Stress management: Direction: none established. No trial measured cortisol or stress responses; surveyed users reported anxiety less often than non-users, self-reported and uncontrolled (Kaeberlein et al., 2023). Periods of acute illness are when common practice pauses dosing.

Monitoring Protocol & Defining Success

Baseline testing before the first dose establishes reference values for the markers rapamycin is known to shift: a fasting lipid panel, HbA1c and fasting glucose, complete blood count, kidney and liver panels, urine protein and, in men, testosterone. PEARL performed most of these tests at baseline (Moel et al., 2025).

Ongoing monitoring follows the PEARL safety schedule: at 2 and 4 weeks after starting, then at 24 and 48 weeks (Moel et al., 2025), with common practice moving to every 3–6 months once values are stable. A sirolimus blood level 48 hours after a dose, the least variable time point (Wallgren et al., 2026), is rechecked after any change of dose, product or interacting drug. Success is defined as stable safety markers with no new adverse events, since no validated marker of slowed aging exists.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Sirolimus whole-blood level (48 hours post-dose) No established target; track own level after each dose or product change Expected change: confirms exposure Weekly dosing gives pre-dose levels below the immunosuppressive range (Wallgren et al., 2026); the LAM trough target of 5–15 ng/mL is a disease target (Rapamune prescribing information); results differ between laboratory assays
LDL cholesterol No established target; track change from own pre-treatment baseline Safety check: a rise prompts diet, drug or dose change Fasting 9–12 hours; rose versus placebo (Stanfield et al., 2026); pair with total cholesterol
Triglycerides No established target; track change from own pre-treatment baseline Safety check: a rise prompts diet, drug or dose change Fasting 9–12 hours; label defines hypertriglyceridemia as above 500 mg/dL (Rapamune prescribing information)
HbA1c No established target; track change from own pre-treatment baseline Safety check and expected change: may rise No fasting needed; rose versus placebo (Stanfield et al., 2026); pair with fasting glucose
Fasting glucose 65–99 mg/dL (standard reference range) Safety check: rising values prompt dose review Morning sample after an 8-hour fast; track change from own baseline
Hemoglobin and platelets (complete blood count) Hemoglobin 13.2–17.1 g/dL (men), 11.7–15.5 g/dL (women); platelets 140–400 ×10⁹/L (standard reference range) Safety check: falls prompt pause or dose reduction Red-cell declines reported (Kraig et al., 2018); include mean red-cell volume
White blood cell count 3.8–10.8 ×10⁹/L (standard reference range) Safety check: low counts raise infection risk Part of complete blood count; leukopenia (low white count) is a labeled reaction
BUN and creatinine BUN 7–25 mg/dL; creatinine 0.6–1.3 mg/dL (standard reference range) Safety check: kidney function BUN rose in men on 10 mg in PEARL (Moel et al., 2025); dehydration raises BUN
Urine protein-to-creatinine ratio Below 0.2 g/g (standard reference range) Safety check: proteinuria prompts dose review First-morning spot urine; label calls for periodic quantitative monitoring
Liver enzymes (ALT, AST) ALT about 7–55 U/L, AST about 8–48 U/L (standard reference range; lab-specific) Safety check: liver impairment raises drug exposure ALT and AST: alanine and aspartate aminotransferase, enzymes released by damaged liver cells
Total testosterone (men) 264–916 ng/dL (standard reference range) Safety check: decline may prompt dose review Morning draw (7–10 am); lower levels reported on sirolimus (Kaczmarek et al., 2004)

Qualitative markers:

  • Frequency and severity of mouth ulcers
  • Frequency and duration of infections, and recovery time from minor illness
  • Healing speed of minor cuts and dental work
  • Energy, exercise performance and recovery from training
  • Gastrointestinal comfort (nausea, diarrhea)
  • Menstrual regularity in women; libido and morning erections in men
  • Self-rated general health and bodily pain

Emerging Research

  • RAP PAC dose-finding: NCT05949658, phase 1, 72 adults aged 55–89, 6 weeks of sirolimus or everolimus 5, 10 or 15 mg weekly; primary outcome side effects severe enough to cap the dose; recruiting, completion 2028. Clean safety at 10–15 mg would support higher weekly doses; toxicity at 5–10 mg would narrow the safety margin.
  • REACH in early Alzheimer’s disease: NCT04629495, phase 2, 40 adults with mild cognitive impairment or early Alzheimer’s, 1 mg daily or placebo for 12 months; safety primary; active, not recruiting, completion 2027. Positive results would open a brain-health benefit; null or adverse results would echo the pilot’s biomarker rises.
  • APOE4 carriers: NCT07728175, phase 1, 225 women aged 45–65 carrying APOE4, sirolimus or placebo daily for about 4 weeks; primary outcome cerebral blood flow; recruiting, completion 2028. A positive result would add a controlled signal, though cerebral blood flow remains an unvalidated marker; a null result would retire the item.
  • Pharmacology in older adults: NCT06727305, phase 1/2, 60 older adults, sirolimus or everolimus 0.5–2 mg daily titrated to 5–7 ng/mL, measuring exposure, S6K activity (a readout of mTORC1 inhibition) and physical performance; recruiting, completion 2027. Positive results would define dose–target relationships; null results would question daily low-dose regimens.
  • RESTOR dose-finding and placebo-controlled trial: NCT06658093, early phase 1, 194 adults aged 65–90; rapamycin or everolimus dose-finding, then 6 months of optimized daily or intermittent dosing versus placebo, 6-month follow-up; primary outcomes drug levels and mTORC1 inhibition; recruiting, completion 2028. Clean target inhibition would support intermittent regimens; no inhibition would question current low doses.
  • EVERLAST: NCT05835999, phase 2, 106 participants; everolimus 0.5 mg daily or 5 mg weekly for 24 weeks in insulin-resistant adults aged 55–80; primary outcome insulin sensitivity; completed July 2026, no results posted. Preserved insulin sensitivity on weekly dosing would support intermittent regimens; worsening would strengthen the glucose risk.
  • TRIAD dog lifespan trial: No NCT ID (veterinary). Per its Tufts Cummings School trial listing, this placebo-controlled trial tests whether rapamycin extends lifespan and improves health measures in healthy companion dogs aged 7 years or older. Longer dog lifespan would be the strongest non-rodent evidence; no effect would weaken translation from mice.
  • Gaps in the human evidence: A systematic review found no endocrine, muscle or neurological benefit and unassessed organ systems (Lee et al., 2024); weekly-versus-daily comparisons of glucose and lipid effects would resolve the central trade-off (Konopka & Lamming, 2023).
  • Findings that could weaken the case: Attenuated exercise gains (Stanfield et al., 2026) and rising brain-injury biomarkers in early Alzheimer’s disease (Gonzales et al., 2025) await larger controlled trials; confirmation would tilt the balance against use in active older adults.

Conclusion

Rapamycin is a transplant drug that turns down a central growth switch in cells, and it has extended lifespan in laboratory animals, including mice treated late in life. For health-focused adults weighing it, the human evidence is far thinner than that animal record. Its established uses, in transplantation and a rare lung disease, rely on doses unlike longevity regimens. In healthy older adults, small trials of weekly doses have produced mixed signals on body composition and well-being, a closely related drug improved vaccine responses, and no study has shown longer or healthier human lives.

The risks are better documented than the benefits. Mouth sores were the only condition weekly users reported more often than non-users, and modest rises in blood fats and blood sugar, more minor side effects and possibly smaller gains from exercise have appeared in controlled trials. Serious harms seen at transplant doses, including poor wound healing, reduced fertility and more deaths among transplant patients, are unmeasured at weekly doses, where serious infection has appeared once; none can be ruled out. The amount reaching the blood varies widely between factory-made and pharmacy-made products and with common drug and food interactions.

The overall evidence is weak: short, small studies, often run by companies that prescribe the drug or by advocates of its use, alongside older transplant data from the manufacturer’s own trials. For this audience, rapamycin remains an experiment with a plausible biological basis, a real but largely manageable side-effect profile, and an unknown long-term payoff.

Top - Benefits - Risks - Protocol